GlassScriptPhysician profile
Raquel Menchaca
NPI 1528283413
$7,648.89
in general payments reported to CMS, 2019-2025
8 companies · $776 in 2025
The $776 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,123 · 2022: $1,594 · 2023: $1,749 · 2024: $1,406 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,931.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,268.89 | 2021-2023 | Symtuza |
| Gilead Sciences, INC. | $2,080.22 | 2021-2025 | Biktarvy |
| Janssen Products, LP | $1,443.73 | 2021-2023 | Symtuza |
| Viiv Healthcare Company | $1,155.68 | 2022-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $295.69 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $266.50 | 2024 | Nuzyra |
| Abbott Laboratories | $118.28 | 2025 | Freestyle Libre 3 |
| Janssen Scientific Affairs, LLC | $19.90 | 2023 | Symtuza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raquel Menchaca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.